Home Analysts Viewpoint Taking a look at what insiders are doing to gauge the Clovis Oncology Inc. (CLVS)’s direction

Taking a look at what insiders are doing to gauge the Clovis Oncology Inc. (CLVS)’s direction

Taking a look at what insiders are doing to gauge the Clovis Oncology Inc. (CLVS)’s direction

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Clovis Oncology Inc. shares valued at $4,188 were sold by Rolfe Lindsey on Nov 02. At $0.98 per share, Rolfe Lindsey sold 4,261 shares. The insider’s holdings dropped to 111,419 shares worth approximately $0.1 million following the completion of this transaction.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Also, MUEHL DANIEL W sold 4,579 shares, netting a total of over 4,501 in proceeds. Following the sale of shares at $0.98 each, the insider now holds 102,271 shares.

Before that, Harding Thomas C. had sold 63 shares from its account. In a trade valued at $62, the insider traded Clovis Oncology Inc. shares for $0.98 each. Upon closing the transaction, the insider’s holdings decreased to 63 shares, worth approximately $3572.9399999999996.

As published in a research note from H.C. Wainwright on May 06, 2022, Clovis Oncology Inc. [CLVS] has been rated down from a Buy to a Neutral. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in mid May. As of April 27, 2020, SVB Leerink has decreased its “Mkt perform” rating to a “an Underperform” for CLVS. Earlier on April 09, 2020, BofA/Merrill downgraded its rating. Their new recommendation was “an Underperform” for CLVS stock which previously was a “a Neutral”.

Analyzing CLVS Stock Performance

On Thursday, Clovis Oncology Inc. [NASDAQ: CLVS] rose 5.62% to $0.94. The stock’s lowest price that day was $0.8814, but it reached a high of $0.9887 in the same session. During the last five days, there has been a drop of approximately -9.62%. Over the course of the year, Clovis Oncology Inc. shares have dropped approximately -65.31%. Shares of the company reached a 52-week high of $3.2500 on 07/08/22 and a 52-week low of $0.5810 on 06/13/22. A 50-day SMA is recorded $1.1492, while a 200-day SMA reached $1.5367. Nevertheless, trading volume fell to 2.42 million shares from 2.6 million shares the previous day.

Support And Resistance Levels for Clovis Oncology Inc. (CLVS)

According to the 24-hour chart, there is a support level at 0.8847, which, if violated, would cause prices to drop to 0.8294. In the upper region, resistance lies at 0.9920. The next price resistance is at 1.0440. RSI (Relative Strength Index) is 37.65 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1160, which suggests the price will decrease in the coming days. Percent R is at 83.40%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Clovis Oncology Inc. subject to short interest?

Stocks of Clovis Oncology Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -12.67 million shares to 28.58 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 41.25 million shares. A decline of -44.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 1.08 of the overall float, the days-to-cover ratio (short ratio) decline to 1.08.

Which companies own the most shares of Clovis Oncology Inc. (CLVS)?

According to The Vanguard Group, Inc. filings, the company currently owns 11,158,703 shares, which is about 7.72% of the total CLVS shares outstanding. The investor’s shares have plunged by -914,537 from its previous 13-F filing of 12073240.0 shares. With the completion of the buy transaction, Millennium Management LLC’s stake is now worth $6,426,386. A total of 828,400 shares of Clovis Oncology Inc. were sold by Renaissance Technologies LLC during the quarter, and 1,595,000 were bought by QVT Financial LP. In its current portfolio, Geode Capital Management LLC holds 1,377,710 shares valued at $1.64 million.

In terms of Clovis Oncology Inc. share price expectations, FactSet research, analysts set an average price target of $2.00 in the next 12 months, up nearly 124.72% from the previous closing price of $0.89. Analysts anticipate Clovis Oncology Inc. stock to reach $2.00 by 2022, with the lowest price target being $2.00. In spite of this, 3 analysts ranked Clovis Oncology Inc. stock as a Hold at the end of 2022. On January 08, 2020, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $27.


Please enter your comment!
Please enter your name here